search
Back to results

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan + hydrochlorothiazide
Telmisartan
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of mild-to-moderate hypertension
  • Patients who fail to respond adequately to telmisartan monotherapy
  • Participants between 18 and 80 years of age
  • Willingness and ability to provide written informed consent

Exclusion Criteria:

  • Patients taking more than three anti-hypertensive medications at the screening visit
  • Pre-menopausal women

    • Who are not surgically sterile
    • Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
  • Any women:

    • Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 3)
    • Who is nursing
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters

    • SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
  • Known or suspected secondary hypertension
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • PTCA (percutaneous transluminal coronary angioplasty) within the past three months
  • History of symptoms characteristic of angioedema during treatment with ACE inhibitors, angiotension II antagonists, thiazide diuretics, β-blockers or calcium channel blockers
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with Type I or Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
  • Known drug or alcohol dependency within the past one year period
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan (except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.321 open-label extension study) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Telmisartan + hydrochlorothiazide and matching placebo

    Telmisartan and matching placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from baseline in seated diastolic blood pressure (DBP)

    Secondary Outcome Measures

    Change from baseline in seated systolic blood pressure (SBP)
    Blood pressure control
    Systolic blood pressure response
    Incidence of adverse events
    Change from baseline in physical examination
    Change from baseline in heart rate
    Change from baseline in laboratory parameters
    Change from baseline in 12-lead ECG (electrocardiogram)

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177500
    Brief Title
    Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy
    Official Title
    An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2000 (undefined)
    Primary Completion Date
    May 2000 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and systolic blood pressure in patients who fail to respond adequately to telmisartan monotherapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    327 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan + hydrochlorothiazide and matching placebo
    Arm Type
    Experimental
    Arm Title
    Telmisartan and matching placebo
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan + hydrochlorothiazide
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Change from baseline in seated diastolic blood pressure (DBP)
    Time Frame
    baseline and after 8 weeks of treatment
    Secondary Outcome Measure Information:
    Title
    Change from baseline in seated systolic blood pressure (SBP)
    Time Frame
    baseline and after 8 weeks of treatment
    Title
    Blood pressure control
    Time Frame
    8 weeks
    Title
    Systolic blood pressure response
    Time Frame
    8 weeks
    Title
    Incidence of adverse events
    Time Frame
    up to 16 weeks
    Title
    Change from baseline in physical examination
    Time Frame
    Baseline and day 56
    Title
    Change from baseline in heart rate
    Time Frame
    Baseline, day 28 and 56
    Title
    Change from baseline in laboratory parameters
    Time Frame
    Baseline and day 56
    Title
    Change from baseline in 12-lead ECG (electrocardiogram)
    Time Frame
    Baseline and day 56

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: History of mild-to-moderate hypertension Patients who fail to respond adequately to telmisartan monotherapy Participants between 18 and 80 years of age Willingness and ability to provide written informed consent Exclusion Criteria: Patients taking more than three anti-hypertensive medications at the screening visit Pre-menopausal women Who are not surgically sterile Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives Any women: Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 3) Who is nursing Hepatic and/or renal dysfunction as defined by the following laboratory parameters SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal Serum creatinine > 2.3 mg/dL Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline Known or suspected secondary hypertension Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV) Unstable angina within the past three months Stroke within the past six months Myocardial infarction or cardiac surgery within the past three months PTCA (percutaneous transluminal coronary angioplasty) within the past three months History of symptoms characteristic of angioedema during treatment with ACE inhibitors, angiotension II antagonists, thiazide diuretics, β-blockers or calcium channel blockers Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Administration of digoxin or other digitalis-type drugs Patients with Type I or Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10% Known drug or alcohol dependency within the past one year period Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan (except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.321 open-label extension study) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study Known hypersensitivity to any component of the formulations Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.323_U00-3262.pdf
    Description
    Related Info

    Learn more about this trial

    Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

    We'll reach out to this number within 24 hrs